The safety and efficacy of Vitamin K antagonist in atrial fibrillation patients with previous ulcer bleeding Long-term results from a multicenter study

Seung Jun Lee, Jung Hoon Sung, Jin Bae Kim, Min Soo Ahn, Hye Young Lee, Jae Sun Uhm, Hui Nam Pak, Moon Hyoung Lee, Jong Yun Kim, Boyoung Joung

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

This study aimed to evaluate the safety and efficacy of Vitamin K antagonist (VKA) in atrial fibrillation (AF) patients with previous ulcer bleeding. In this multicenter, retrospective analysis, clinical outcomes of 754 AF patients with a history of ulcer bleeding were evaluated. After ulcer treatment, 458 patients (61%) were treated with VKA, and the outcomes were compared to 296 patients (39%) without VKA. VKA treatment significantly increased major bleeding (7.3%/year vs 3.2%/year, P<0.001), and reduced major adverse cardiac events (MACE) (5.4%/year vs 10.0%/year, P<0.001). Specifically, risk of gastrointestinal bleeding was significantly higher in the VKA group than no-VKA group (5.7%/year vs 2.6%/year, P<0.001). Consequently, there was no difference in the incidence of composite of a MACE and major bleeding, between the 2 groups. In patients with time in the therapeutic range (TTR) ?65%, VKA significantly decreased MACE (2.8%/year vs 10.0%/year, P<0.001) without increasing major bleeding. Net clinical benefit model showed beneficial effects of VKA in patients with TTR ?65%, and harmful effects in those with TTR<55%. In AF patients with previous ulcer bleeding, VKA treatment did not improve clinical outcomes unless the international normalized ratio level was constantly maintained (TTR ?65%), as the gastrointestinal bleeding (GIB) risk significantly increased.

Original languageEnglish
Article numbere5467
JournalMedicine (United States)
Volume95
Issue number47
DOIs
Publication statusPublished - 2016

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'The safety and efficacy of Vitamin K antagonist in atrial fibrillation patients with previous ulcer bleeding Long-term results from a multicenter study'. Together they form a unique fingerprint.

  • Cite this